Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations study observed that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7,